MedTrace Logo

Study of MG-ZG122 Humanized Monoclonal Antibody in Asthma Subjects

NCT07054034 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2025-07-08

No results posted yet for this study

Summary

A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of MG-ZG122 Humanized Monoclonal Antibody Injection in Asthma Subjects, with Dosing Every 12 or 24 Weeks for 48 Weeks

Conditions

  • Bronchial Asthma

Interventions

DRUG

MG-ZG122 Humanized Monoclonal Antibody Injection

MG-ZG122 Humanized Monoclonal Antibody Injection

OTHER

Placebo

MG-ZG122 Humanized Monoclonal Antibody Injection Placebo

Sponsors & Collaborators

  • Shanghai Mabgeek Biotech.Co.Ltd

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-11
Primary Completion
2026-05-26
Completion
2027-05-26

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07054034 on ClinicalTrials.gov